Compare FIVN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVN | AGIO |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2014 | 2013 |
| Metric | FIVN | AGIO |
|---|---|---|
| Price | $15.71 | $27.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 8 |
| Target Price | $26.32 | ★ $37.63 |
| AVG Volume (30 Days) | ★ 2.7M | 708.3K |
| Earning Date | 05-21-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 364.71 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $1,149,088,000.00 | $43,011,000.00 |
| Revenue This Year | $11.39 | $75.68 |
| Revenue Next Year | $10.00 | $167.63 |
| P/E Ratio | $36.13 | ★ N/A |
| Revenue Growth | ★ 10.28 | N/A |
| 52 Week Low | $15.70 | $22.24 |
| 52 Week High | $31.75 | $46.00 |
| Indicator | FIVN | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.61 | 46.37 |
| Support Level | N/A | $26.48 |
| Resistance Level | $20.04 | $29.49 |
| Average True Range (ATR) | 0.90 | 1.13 |
| MACD | -0.17 | -0.17 |
| Stochastic Oscillator | 0.00 | 25.09 |
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.